| Literature DB >> 26124996 |
Jung Soo Lim1, Young Ju Choi2, Soo-Kyung Kim3, Byoung Wook Huh2, Eun Jig Lee4, Kap Bum Huh2.
Abstract
BACKGROUND: Visceral obesity is the most powerful contributor to the development of metabolic syndrome (MetS) and cardiovascular diseases. In light of visceral obesity, however, there is a paucity of data on the appropriate cutoff point of waist circumference (WC) in subjects with type 2 diabetes. The aim of this study was to investigate the optimal cutoff value for WC that signals insulin resistance (IR) and visceral obesity in Koreans with type 2 diabetes.Entities:
Keywords: Diabetes mellitus, type 2; Insulin resistance; Obesity, abdominal; Waist circumference
Year: 2015 PMID: 26124996 PMCID: PMC4483611 DOI: 10.4093/dmj.2015.39.3.253
Source DB: PubMed Journal: Diabetes Metab J ISSN: 2233-6079 Impact factor: 5.376
Baseline characteristics
| Characteristic | Total ( | Men ( | Women ( |
|---|---|---|---|
| Age, yr | 57.24±10.27 | 55.47±10.80 | 59.17±9.27 |
| DM duration, yr | 7.22±6.89 | 7.04±7.04 | 7.43±6.71 |
| Body mass index, kg/m2 | 24.69±3.39 | 24.61±3.24 | 24.77±3.55 |
| Waist circumference, cm | 84.60±8.14 | 87.26±7.38 | 81.69±7.95 |
| Systolic blood pressure, mm Hg | 136.04±17.93 | 134.39±17.22 | 137.86±18.51 |
| Diastolic blood pressure, mm Hg | 86.91±11.24 | 88.24±11.31 | 85.44±10.97 |
| 1.96±0.92 | 1.95±0.91 | 1.98±0.93 | |
| Fasting glucose, mg/dL | 157.81±56.79 | 159.44±56.72 | 156.02±56.83 |
| C-peptide, ng/mL | 2.11±0.85 | 2.14±0.84 | 2.08±0.87 |
| Glycosylated hemoglobin, % | 8.28±1.83 | 8.30±1.90 | 8.26±1.74 |
| Total cholesterol, mg/dL | 197.07±40.94 | 192.34±40.35 | 202.25±40.95 |
| Triglyceride, mg/dL | 161.84±115.30 | 166.17±126.98 | 157.11±100.82 |
| HDL-C, mg/dL | 48.94±12.74 | 46.90±12.14 | 51.19±13.00 |
| LDL-C, mg/dL | 115.55±34.15 | 112.60±32.77 | 118.79±35.34 |
| Visceral fat thickness, mm | 46.14±17.54 | 49.75±17.35 | 42.19±16.88 |
| CIMT, mm | 0.833±0.182 | 0.847±0.185 | 0.818±0.179 |
| Medications for dyslipidemia, % | 698 (16.4) | 314 (14.1) | 384 (18.9) |
| Medications for hypertension, % | 1,207 (28.4) | 562 (25.3) | 645 (31.7) |
| Antidiabetic treatment, % | |||
| Insulin | 450 (10.6) | 193 (8.7) | 257 (12.6) |
| Oral medicationsa | 2,497 (58.7) | 1,234 (55.6) | 1,263 (62.2) |
| Only diet and exercise | 1,305 (30.7) | 793 (35.7) | 512 (25.2) |
| MetS components, %b | |||
| Hypertriglyceridemia | 2,127 (50.0) | 1,059 (47.7) | 1,068 (52.6) |
| Low HDL-C | 1,600 (37.6) | 589 (26.7) | 1,011 (50.4) |
| Hypertension | 3,147 (75.0) | 1,643 (74.9) | 1,504 (75.0) |
| More than 2 factors | 2,288 (54.6) | 1,068 (48.7) | 1,220 (61.1) |
Values are presented as mean±standard deviation or number (%).
DM, diabetes mellitus; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; CIMT, carotid intima-media thickness; MetS, metabolic syndrome.
aOral medications included sulfonylurea, metformin, and α-glucosidase inhibitor, bTriglyceride ≥150 mg/dL or medication; low HDL-C, <40 mg/dL for men and <50 mg/dL for women; blood pressure ≥130/85 mm Hg or antihypertensive medication.
Cutoff values for waist circumference to identify subjects with two or more metabolic components, visceral obesity, and insulin resistance
| Variable | Two or more metabolic risk factorsa | Presence of visceral obesityb | Presence of IRc | |||
|---|---|---|---|---|---|---|
| Sensitivity, % | Specificity, % | Sensitivity, % | Specificity, % | Sensitivity, % | Specificity, % | |
| Men | ||||||
| 85 | 74.1 | 43.9 | 83.6 | 56.0 | 74.3 | 40.2 |
| 86 | 67.7 | 50.1 | 77.9 | 62.8 | 68.8 | 46.8 |
| 87 | 61.0 | 55.9 | 73.0 | 70.5 | 62.1 | 52.7 |
| 88 | 55.5 | 61.0 | 67.6 | 75.5 | 57.5 | 58.4 |
| 89 | 49.3 | 66.1 | 60.5 | 79.8 | 51.2 | 63.8 |
| 90 | 43.4 | 71.3 | 54.2 | 84.4 | 45.7 | 69.2 |
| 95 | 18.5 | 88.7 | 24.5 | 95.9 | 21.9 | 88.9 |
| AUC (95% CI) | 0.616 (0.590-0.641) | 0.777 (0.756-0.798) | 0.610 (0.584-0.636) | |||
| Women | ||||||
| 80 | 66.0 | 49.5 | 76.0 | 66.0 | 70.9 | 45.0 |
| 81 | 60.7 | 55.5 | 70.3 | 71.4 | 66.1 | 51.0 |
| 82 | 55.8 | 58.8 | 65.6 | 74.7 | 61.1 | 54.8 |
| 83 | 49.7 | 63.8 | 59.7 | 80.0 | 55.3 | 60.4 |
| 84 | 44.6 | 68.5 | 53.9 | 83.9 | 50.8 | 65.7 |
| 85 | 39.6 | 73.6 | 47.6 | 86.9 | 45.1 | 70.5 |
| 90 | 18.3 | 90.0 | 21.5 | 95.2 | 21.8 | 88.1 |
| AUC (95% CI) | 0.611 (0.584-0.638) | 0.778 (0.756-0.800) | 0.603 (0.575-0.632) | |||
IR, insulin resistance; AUC, area under the curve; CI, confidence interval.
aHypertriglyceridemia, triglycerides ≥150 mg/dL or taking medication; low high density lipoprotein cholesterol, <40 mg/dL for men and <50 mg/dL for women; hypertension, blood pressure≥130/85 mm Hg or taking antihypertensive medication, bThe presence of visceral obesity was defined as a visceral fat thickness of greater than 47.6 and 35.5 mm in men and women, respectively, cIR was defined as the low tertile of insulin sensitivity.
Fig. 1Receiver operating characteristic analysis of waist circumference (WC) to detect the presence of two or more metabolic components, visceral obesity, and insulin resistance (IR) in (A) men and (B) women with type 2 diabetes. The higher the area under the curve, the greater the predictive power. A WC of 87 cm for men (black circles) and 81 cm for women (black triangles) was chosen as the discriminating value to predict two or more metabolic components, and the presence of visceral obesity and IR. These cutoff points had the highest predictive powers for the presence of visceral obesity. Moreover, they had higher sensitivity and specificity compared to the previous criteria—90 cm for men (black squares) and 85 cm for women (black diamonds)—proposed by the Korean Society for the Study of Obesity. Visceral obesity was defined as a visceral fat thickness of greater than 47.6 mm for men and 35.5 mm for women, and IR was defined as the low tertile of insulin sensitivity.
Differences in insulin sensitivity (Kitt), VFT, and CIMT according to the presence of metabolic syndrome defined by KOSSO criteria and our criteria in subjects with type 2 diabetes
| Variable | KOSSO criteria | Our criteria | ||||
|---|---|---|---|---|---|---|
| MetS | No MetS | MetS | No MetS | |||
| Men, | 463 | 1,746 | 652 | 1,554 | ||
| | 1.63±0.74 | 2.04±0.94 | <0.001 | 1.68±0.78 | 2.07±0.94 | <0.001 |
| VFT, mm | 63.49±16.73 | 46.13±15.56 | <0.001 | 60.23±16.86 | 45.36±15.54 | <0.001 |
| CIMT, mm | 0.851±0.189 | 0.846±0.184 | 0.666 | 0.849±0.188 | 0.846±0.184 | 0.729 |
| Women, | 483 | 1,530 | 740 | 1,265 | ||
| | 1.66±0.79 | 2.07±0.95 | <0.001 | 1.70±0.80 | 2.13±0.96 | <0.001 |
| VFT, mm | 54.97±17.43 | 38.15±14.52 | <0.001 | 50.91±16.96 | 37.08±14.62 | <0.001 |
| CIMT, mm | 0.828±0.182 | 0.817±0.177 | 0.244 | 0.834±0.184 | 0.811±0.174 | 0.007 |
Values are presented as mean±standard deviation.
KOSSO, Korean Society for the Study of Obesity; MetS, metabolic syndrome; VFT, visceral fat thickness; CIMT, carotid intima-media thickness.
Fig. 2Differences in the prevalence of metabolic components according to Korean Society for the Study of Obesity (KOSSO) criteria and our criteria in (A) men and (B) women with type 2 diabetes. Compared to metabolic syndrome (MetS) as defined by the KOSSO criteria, the prevalence of each metabolic component, including hypertriglyceridemia (hyper-TG), low high density lipoprotein (HDL) cholesterol, and hypertension (HTN), was significantly greater in both sexes when our criteria were used to define MetS.
Baseline characteristics according to insulin sensitivity (kitt%)
| Characteristic | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|
| Low tertile | Middle tertile | High tertile | Low tertile | Middle tertile | High tertile | |||
| Age, yr | 56.84±11.72 | 56.76±10.99 | 55.01±10.54a,b | <0.001 | 60.22±9.92 | 60.30±9.31 | 58.67±9.54a,b | <0.001 |
| DM duration, yr | 8.39±7.63 | 7.36±7.05a | 6.38±6.62a,b | <0.001 | 9.02±6.76 | 7.57±6.70a | 6.48±6.42a,b | <0.001 |
| Body mass index, kg/m2 | 24.69±3.35 | 24.54±3.35 | 24.34±3.16 | 0.071 | 24.58±3.28 | 24.63±3.26 | 24.76±3.59 | 0.52 |
| Waist circumference, cm | 89.25±7.85 | 87.59±7.17a | 85.05±7.12a,b | <0.001 | 83.64±8.15 | 81.87±7.50a | 79.48±8.10a,b | <0.001 |
| 1.04±0.29 | 1.86±0.23a | 3.08±0.64a,b | <0.001 | 1.06±0.29 | 1.86±0.22a | 3.04±0.68a,b | <0.001 | |
| Fasting glucose, mg/dL | 184.82±65.57 | 153.65±50.30a | 137.87±41.19a,b | <0.001 | 184.28±64.10 | 149.74±50.52a | 134.65±43.01a,b | <0.001 |
| C-peptide, ng/mL | 2.35±0.92 | 2.08±0.73a | 1.88±0.75a,b | <0.001 | 2.29±0.98 | 2.03±0.78a | 1.77±0.67a,b | <0.001 |
| HbA1c, % | 9.07±2.02 | 8.17±1.74a | 7.75±1.70a,b | <0.001 | 9.10±1.83 | 8.20±1.69a | 7.63±1.45a,b | <0.001 |
| Total cholesterol, mg/dL | 198.39±44.22 | 193.35±37.21a | 186.56±37.91a,b | <0.001 | 209.65±44.00 | 204.43±40.82a | 199.37±39.44a,b | <0.001 |
| Triglyceride, mg/dL | 189.50±143.78 | 161.09±109.20a | 134.80±83.53a,b | <0.001 | 184.68±119.44 | 155.30±93.79a | 128.25±77.02a,b | <0.001 |
| HDL-C, mg/dL | 46.42±12.25 | 46.75±11.72 | 48.27±12.17a,b | 0.001 | 49.39±12.16 | 51.34±13.24a | 52.32±13.07a | <0.001 |
| LDL-C, mg/dL | 115.53±36.53 | 113.63±31.09 | 109.77±31.34a | 0.001 | 122.74±36.71 | 120.26±35.54 | 118.92±33.72 | 0.09 |
| VFT, mm | 54.36±18.66 | 50.50±17.19a | 45.25±16.13a,b | <0.001 | 46.81±17.86 | 43.05±16.46a | 37.24±15.39a,b | <0.001 |
| CIMT, mm | 0.857±0.205 | 0.850±0.186 | 0.823±0.184a,b | <0.001 | 0.824±0.185 | 0.807±0.171 | 0.794±0.178a | 0.001 |
| MetS componentsc | ||||||||
| Hypertriglyceridemia | 641 (57.4) | 560 (50.0) | 408 (36.7) | <0.001 | 670 (64.4) | 540 (51.9) | 404 (38.9) | <0.001 |
| Low HDL-C | 306 (27.6) | 279 (25.1) | 238 (21.6) | 0.004 | 568 (55.0) | 530 (51.6) | 478 (47.0) | 0.001 |
| Hypertension | 871 (79.4) | 836 (75.5) | 760 (69.7) | <0.001 | 801 (77.7) | 770 (75.8) | 711 (70.1) | <0.001 |
| More than 2 factors | 623 (56.7) | 539 (48.8) | 414 (37.8) | <0.001 | 730 (71.1) | 639 (62.8) | 510 (50.7) | <0.001 |
Values are presented as mean±standard deviation or number (%).
DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; VFT, visceral fat thickness; CIMT, carotid intima-media thickness; MetS, metabolic syndrome.
aP<0.05 vs. low tertile, bP<0.05 vs. middle tertile, cHypertriglyceridemia, triglycerides ≥150 mg/dL or taking medication; low HDL-C, <40 mg/dL for men and <50 mg/dL for women; hypertension, blood pressure ≥130/85 mm Hg or taking antihypertensive medication.